Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune· 16 minutes agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company’s first quarter ...
No More Yearly Flu Shots? Vaccine Mixed From 80,000 Proteins Could Be The Key
IFLScience· 7 hours agoA new vaccine strategy could spell the end of yearly flu shots, by targeting part of the virus that...
Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views
Investor's Business Daily· 2 hours agoUnion is planning to buy up to 36 million doses of its Covid vaccine each year for at least four...
Bird Flu is bad for poultry and cattle. Why it's not a dire threat for most of us — yet
NBC NEWS· 9 minutes agoHeadlines are flying after the Department of Agriculture confirmed that the H5N1 bird flu virus has...
Bird Flu: What's The Latest And How Worried Should We Be?
IFLScience· 6 hours agoBird flu seems to be perennially in the news at the moment, and with more and more species...
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent...
WRBL Columbus· 8 hours agoflu seasons in the United States. SUMMIT, N.J., May 2, 2024 /PRNewswire/ -- CSL...published in Open Forum Infectious Diseases (OFID), showing that a cell-based quadrivalent ...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga· 2 hours agoModerna added that clinical development and manufacturing expenses also decreased, driven by lower...
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 6 hours agoLast year, Moderna reported encouraging data from a phase III immunogenicity study (P303) and a...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 11 hours agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 5 hours agoBut Moderna expects the lion's share of its sales to come in the second half of 2024. That lines up...